Advanced search
Publication Cover
Vascular Health and Risk Management Volume 6, 2010 - Issue
Submit an article Journal homepage
79
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

Peter Bramlage1 Institute for Cardiovascular Pharmacology and Epidemiology, MahlowCorrespondence[email protected]
,
Wolf-Peter Wolf2 Daiichi Sankyo Deutschland GmbH, Munich, Germany
,
Thomas Stuhr2 Daiichi Sankyo Deutschland GmbH, Munich, Germany
,
Eva-Maria Fronk3 Daiichi Sankyo Europe GmbH, Munich, Germany
,
Wolfhard Erdlenbruch2 Daiichi Sankyo Deutschland GmbH, Munich, Germany
,
Reinhard Ketelhut4 Department of Sports Medicine, Universitätsklinikum Berlin
&
Roland E Schmieder5 Department of Nephrology and Hypertension, University Hospital of Erlangen, Germany
 show all
Pages 803-811 | Published online: 27 Aug 2010

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Peter Bramlage, Wolf-Peter Wolf, Eva-Maria Fronk, Thomas Stuhr, Wolfhard Erdlenbruch, Jürgen Wasem, Reinhard Ketelhut & Roland E Schmieder. (2010) Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care. Expert Opinion on Pharmacotherapy 11:17, pages 2779-2790.
Read now

Articles from other publishers (9)

Sverre E. Kjeldsen, Gloria Cha, Giuseppe Villa & Giuseppe Mancia. (2016) Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses. The Journal of Clinical Pharmacology 56:9, pages 1120-1129.
Crossref
Peter Bramlage, Roland E. Schmieder, Anselm K. Gitt, Peter Baumgart, Felix Mahfoud, Hartmut Buhck, Taoufik Ouarrak, Martina Ehmen & Sebastian A. Potthoff. (2015) The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. Trials 16:1.
Crossref
Claudio Borghi, Martino Morbini & Arrigo F.G. Cicero. (2015) Combination therapy in the extended cardiovascular continuum. Journal of Cardiovascular Medicine 16:5, pages 390-399.
Crossref
Xinhuan Wan, Panqin Ma & Xiangrong Zhang. (2014) A promising choice in hypertension treatment: Fixed-dose combinations. Asian Journal of Pharmaceutical Sciences 9:1, pages 1-7.
Crossref
Anselm K Gitt, Peter Baumgart, Peter Bramlage, Felix Mahfoud, Sebastian A Potthoff, Jochen Senges, Steffen Schneider, Hartmut Buhck & Roland E Schmieder. (2013) EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry. BMC Cardiovascular Disorders 13:1.
Crossref
Massimo Volpe & Giuliano Tocci. (2013) Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs & Aging 30:12, pages 987-998.
Crossref
Manuel Gorostidi & Alejandro de la Sierra. (2013) Combination Therapy in Hypertension. Advances in Therapy 30:4, pages 320-336.
Crossref
Serap Erdine. (2012) Olmesartan/amlodipine: blood pressure lowering and beyond in special populations. Therapeutic Advances in Cardiovascular Disease 6:1, pages 31-44.
Crossref
Martin Thoenes, Ulrich Tebbe, Ludger Rosin, W. Dieter Paar, Peter Bramlage, Wilhelm Kirch & Michael Böhm. (2011) Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clinical Research in Cardiology 100:6, pages 483-491.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.